Cover Image
市場調查報告書

Abiogen Pharma S.p.A. - 產品平台檢討

Abiogen Pharma S.p.A. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 214144
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
Abiogen Pharma S.p.A. - 產品平台檢討 Abiogen Pharma S.p.A. - Product Pipeline Review - 2015
出版日期: 2015年03月26日 內容資訊: 英文 23 Pages
簡介

Abiogen Pharma S.p.A. ha致力於研究開發及製造呼吸系統,糖尿病,骨骼代謝等各種領域的治療藥。

本報告提供Abiogen Pharma S.p.A.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Abiogen Pharma S.p.A.的基本資料

Abiogen Pharma S.p.A.概要

  • 主要資訊
  • 企業資料

Abiogen Pharma S.p.A.:R&D概要

  • 主要的治療範圍

Abiogen Pharma S.p.A.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Abiogen Pharma S.p.A.:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Abiogen Pharma S.p.A.:藥物簡介

  • neridronic acid
  • clodronate disodium
  • Combotox
  • (clodronate + hyaluronic acid)

Abiogen Pharma S.p.A.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Abiogen Pharma S.p.A.:暫停中的計劃

Abiogen Pharma S.p.A.:總公司和子公司的所地

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06859CDB

Summary

Global Markets Direct's, 'Abiogen Pharma S.p.A. - Product Pipeline Review - 2015', provides an overview of the Abiogen Pharma S.p.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Abiogen Pharma S.p.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Abiogen Pharma S.p.A. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Abiogen Pharma S.p.A.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Abiogen Pharma S.p.A.'s pipeline products

Reasons to buy

  • Evaluate Abiogen Pharma S.p.A.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Abiogen Pharma S.p.A. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Abiogen Pharma S.p.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Abiogen Pharma S.p.A. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Abiogen Pharma S.p.A.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Abiogen Pharma S.p.A. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Abiogen Pharma S.p.A. Snapshot
    • Abiogen Pharma S.p.A. Overview
    • Key Information
    • Key Facts
  • Abiogen Pharma S.p.A. - Research and Development Overview
    • Key Therapeutic Areas
  • Abiogen Pharma S.p.A. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Abiogen Pharma S.p.A. - Pipeline Products Glance
    • Abiogen Pharma S.p.A. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Abiogen Pharma S.p.A. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
  • Abiogen Pharma S.p.A. - Drug Profiles
    • clodronate disodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • neridronic acid
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (clodronate disodium + hyaluronic acid)
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Abiogen Pharma S.p.A. - Pipeline Analysis
    • Abiogen Pharma S.p.A. - Pipeline Products by Target
    • Abiogen Pharma S.p.A. - Pipeline Products by Route of Administration
    • Abiogen Pharma S.p.A. - Pipeline Products by Molecule Type
    • Abiogen Pharma S.p.A. - Pipeline Products by Mechanism of Action
  • Abiogen Pharma S.p.A. - Recent Pipeline Updates
  • Abiogen Pharma S.p.A. - Dormant Projects
  • Abiogen Pharma S.p.A. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Abiogen Pharma S.p.A., Key Information
  • Abiogen Pharma S.p.A., Key Facts
  • Abiogen Pharma S.p.A. - Pipeline by Indication, 2015
  • Abiogen Pharma S.p.A. - Pipeline by Stage of Development, 2015
  • Abiogen Pharma S.p.A. - Monotherapy Products in Pipeline, 2015
  • Abiogen Pharma S.p.A. - Combination Treatment Modalities in Pipeline, 2015
  • Abiogen Pharma S.p.A. - Phase III, 2015
  • Abiogen Pharma S.p.A. - Phase I, 2015
  • Abiogen Pharma S.p.A. - Pipeline by Target, 2015
  • Abiogen Pharma S.p.A. - Pipeline by Route of Administration, 2015
  • Abiogen Pharma S.p.A. - Pipeline by Molecule Type, 2015
  • Abiogen Pharma S.p.A. - Pipeline Products by Mechanism of Action, 2015
  • Abiogen Pharma S.p.A. - Recent Pipeline Updates, 2015
  • Abiogen Pharma S.p.A. - Dormant Developmental Projects,2015

List of Figures

  • Abiogen Pharma S.p.A. - Pipeline by Top 10 Indication, 2015
  • Abiogen Pharma S.p.A. - Pipeline by Stage of Development, 2015
  • Abiogen Pharma S.p.A. - Pipeline by Top 10 Target, 2015
  • Abiogen Pharma S.p.A. - Pipeline by Top 10 Route of Administration, 2015
  • Abiogen Pharma S.p.A. - Pipeline by Top 10 Molecule Type, 2015
  • Abiogen Pharma S.p.A. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top